National Research (NASDAQ:NRC) Stock Price Passes Above Two Hundred Day Moving Average – What’s Next?

Shares of National Research Corporation (NASDAQ:NRC) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $15.11 and traded as high as $19.20. National Research shares last traded at $19.01, with a volume of 86,131 shares traded.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d+)” rating on shares of National Research in a research report on Monday. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

National Research Stock Up 0.7%

The company has a current ratio of 0.53, a quick ratio of 0.53 and a debt-to-equity ratio of 5.31. The stock has a market cap of $430.77 million, a P/E ratio of 27.16 and a beta of 0.45. The firm has a 50-day simple moving average of $15.40 and a two-hundred day simple moving average of $15.11.

National Research (NASDAQ:NRC) last released its quarterly earnings results on Monday, October 27th. The company reported $0.23 EPS for the quarter. National Research had a net margin of 11.76% and a return on equity of 98.26%. The business had revenue of $34.61 million for the quarter.

National Research Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 9th. Shareholders of record on Friday, December 26th will be given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 3.4%. The ex-dividend date is Friday, December 26th. This is a boost from National Research’s previous quarterly dividend of $0.12. National Research’s dividend payout ratio (DPR) is currently 68.57%.

Institutional Investors Weigh In On National Research

Several institutional investors have recently made changes to their positions in the stock. Los Angeles Capital Management LLC bought a new position in National Research during the 2nd quarter worth $403,000. QV Investors Inc. grew its holdings in shares of National Research by 7.6% during the 2nd quarter. QV Investors Inc. now owns 381,310 shares of the company’s stock worth $6,406,000 after purchasing an additional 26,950 shares in the last quarter. Vanguard Personalized Indexing Management LLC bought a new position in shares of National Research in the second quarter worth $444,000. CWM LLC raised its stake in National Research by 192.0% in the second quarter. CWM LLC now owns 6,847 shares of the company’s stock valued at $115,000 after purchasing an additional 4,502 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in National Research by 4.5% during the first quarter. Rhumbline Advisers now owns 22,204 shares of the company’s stock worth $284,000 after purchasing an additional 946 shares during the period. 47.26% of the stock is currently owned by institutional investors.

About National Research

National Research Corp (NASDAQ: NRC), also known as NRC Health, is a healthcare analytics and performance improvement company specializing in patient and employee experience measurement. The company’s cloud-based platform enables healthcare providers to collect real-time feedback through patient satisfaction surveys, post-discharge outreach, and employee engagement tools. NRC Health integrates clinical, operational and financial data to deliver actionable insights that support quality improvement initiatives and value-based care programs.

Since its founding in the early 1990s and headquartered in Lincoln, Nebraska, National Research has expanded beyond its regional roots to serve more than 1,600 hospitals and 12,000 care sites across the United States and Canada.